Drug combination after surgery for colorectal cancer spread in the belly
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (trifluridine/tipiracil, bevacizumab, and serplulimab) for people with colorectal cancer that has spread to the belly and has already had surgery. The goal is to see if this treatment can help control the cancer and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove cancer spread in your belly (peritoneal metastases), and the surgeon was able to remove most of it.
- Any spread of cancer outside the belly (like to the liver or lungs) is not causing serious problems right now.
- You have already tried standard chemotherapy (like oxaliplatin, irinotecan, or fluorouracil) and it didn't work, or you couldn't handle the side effects.
- Your tumor is 'microsatellite stable' (MSS), which means it doesn't have a certain genetic marker.
- You are at least 18 years old, able to care for yourself (ECOG 0 or 1), and your heart, liver, and kidneys are working well enough.
- Your blood counts meet certain minimums (for example, white blood cells, hemoglobin, and platelets).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—bevacizumab and trifluridine/tipiracil—given together to see if it lowers the risk of a serious drop in white blood cells (neutropenia) in people with advanced colorectal cancer. The goal is to make treatment safer and more tolerable.
This trial tests a combination of two targeted drugs (sintilimab and bevacizumab) with chemotherapy for people whose colorectal cancer has not spread to the liver. It aims to see if this combo helps control the cancer better after the first treatment stops working.
This trial tests a lower dose of a chemotherapy pill (trifluridine/tipiracil) combined with bevacizumab for advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer with fewer side effects.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.